Loading... Please wait... Loading... Please wait...
The Stock Score/Grades evaluate bankruptcy risk and assess the financial strength and fundamental health of a company
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in North America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium and chromium connect instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity on a cell-by-cell basis; single cell immune profiling for measuring the activity of immune cells and their targets; single cell Assay for Transposase Accessible Chromati (ATAC) for measuring epigenetics comprising the physical organization of DNA; and single cell multiome ATAC + gene expression for measuring the genetic activity and epigenetic programming in the same cells across tens of thousands of cells in a single experiment. The company also provides visium spatial gene expression solution for measuring spatial gene expression patterns across a single tissue sample or gene expression and protein co-detection when combined with immunofluorescence. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
The Latest News section aggregates recent news posts from various news outlets, offering a comprehensive overview of the most recent developments related to the topic.
Results indicate strong potential to further expand resources and continue to extend mine life (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - June ...
Researchers used Chromium Single Cell products and Xenium In Situ to profile how gene expression is spatially regulated during secondary palate formation PLEASANTON, Calif., June 27, 2024 /PRNewswire/...
10x Genomics has experienced a significant decline in share price, currently trading around $20 per share, with no bullish indicators for a potential reversal. Recent performance shows growth in total...
New 5,000-plex gene panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , June 20, 2024 /PRNewswire/ -- 10x Genomics, Inc. (Nasdaq: TXG...
PHILADELPHIA, PA / ACCESSWIRE / June 11, 2024 / Kaskela Law LLC announces that it is investigating 10x Genomics, Inc. (NASDAQ:TXG) on behalf of the company's stockholders. The investigation seeks to d...
Pipeline of high-quality targets systematically prioritized to unlock the full potential of Morelos (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - ...
New Xenium Prime 5K Pan-Tissue and Pathways panel increases plex by an order of magnitude and delivers industry-leading speed and throughput PLEASANTON, Calif. , May 29, 2024 /PRNewswire/ -- 10x Ge...
Lab Instrument and Services providers in the healthcare industry can generate high recurring revenues. Many loss-making instrument makers in the industry may not provide meaningful returns and carry h...
Report shines a spotlight on continued excellence in ESG performance and disclosure (All amounts expressed in U.S. dollars unless otherwise stated) Toronto, Ontario--(Newsfile Corp. - May 21, 2024) - ...
